Search Results - Worbes-Cerezo, M

Refine Results
  1. 1
    Health Related Quality of Life Outcomes (Hrqol) and Resource Use Associated With Type 2 Diabetes Patients Taking Steps To Lose Weight In 5 European Countries

    Health Related Quality of Life Outcomes (Hrqol) and Resource Use Associated With Type 2 Diabetes Patients Taking Steps To Lose Weight In 5 European Countries by Nuhoho, S, Vietri, J, Isherwood, G, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland

    The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland by Bacon, T, Willis, M, Johansen, P, Neslusan, C, Nuhoho, S, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)

    The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (... by Diels, J, Angermund, R, Schroeder, M, Worbes-Cerezo, M, Thompson, G

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The Cost-Effectiveness of Canagliflozin Verse Insulin-Secretagogues (Sulphonylureas) or Insulin In Patients With Type 2 Diabetes Mellitus (T2dm) As An Add-On To Metformin In Ireland

    The Cost-Effectiveness of Canagliflozin Verse Insulin-Secretagogues (Sulphonylureas) or Insulin In Patients With Type 2 Diabetes Mellitus (T2dm) As An Add-On To Metformin In Irelan... by Bacon, T, Willis, M, Johansen, P, Neslusan, C, Nuhoho, S, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of Type 2 Diabetes Mellitus (T2dm) Therapy In Ireland?

    Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of Type 2 Diabetes Mellitus (T2dm) Therapy In Ireland? by Bacon, T, Willis, M, Johansen, P, Neslusan, C, Nuhoho, S, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PDB40 The Importance of HbA1C Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM)

    PDB40 The Importance of HbA1C Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM) by Willis, M, He, J, Neslusan, C, Johansen, P, Worbes-cerezo, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    PDB43 The Economic Impact of Weight Loss in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden

    PDB43 The Economic Impact of Weight Loss in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden by Willis, M, Neslusan, C, He, J, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    PDB41 The Cost-Effectiveness of Getting to Glucose, Blood Pressure, and Lipid Goals in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden

    PDB41 The Cost-Effectiveness of Getting to Glucose, Blood Pressure, and Lipid Goals in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Swede... by He, J, Neslusan, C, Willis, M, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    EE152 The Implicit Devaluation of Health Benefits Over Time in NICE Decision-Making Criteria: Assessing NICE’s Static Willingness to Pay Threshold in the Context of Inflation

    EE152 The Implicit Devaluation of Health Benefits Over Time in NICE Decision-Making Criteria: Assessing NICE’s Static Willingness to Pay Threshold in the Context of Inflation by Percival, C., Worbes-Cerezo, M.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study

    Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study by Linertová, Renata, Serrano-Aguilar, Pedro, Posada-de-la-Paz, Manuel, Hens-Pérez, Manuel, Kanavos, Panos, Taruscio, Domenica, Schieppati, Arrigo, Stefanov, Rumen, Péntek, Márta, Delgado, Claudia, Graf von der Schulenburg, Johann-Matthias, Persson, Ulf, Chevreul, Karine, Fattore, Giovanni, Worbes-Cerezo, Melany, Sefton, Mark, López-Bastida, Julio

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  11. 11
    PSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    PSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF) by Sydnor, S., Worbes-Cerezo, M., Lee, J.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    PRM86 - Estimating the Lifetime Health Outcomes of Type 2 Diabetes Mellitus (T2dm) Patients Inadequately Controlled on Metformin Plus Sulphonylurea Receiving Either Canagliflozin or Sitagliptin Using the UKPDS Outcomes Model V1.3

    PRM86 - Estimating the Lifetime Health Outcomes of Type 2 Diabetes Mellitus (T2dm) Patients Inadequately Controlled on Metformin Plus Sulphonylurea Receiving Either Canagliflozin o... by Nuhoho, S., Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Estimating the Lifetime Health Outcomes of Type 2 Diabetes Mellitus (T2dm) Patients Inadequately Controlled on Metformin Plus Sulphonylurea Receiving Either Canagliflozin or Sitagliptin Using the UKPDS Outcomes Model V1.3

    Estimating the Lifetime Health Outcomes of Type 2 Diabetes Mellitus (T2dm) Patients Inadequately Controlled on Metformin Plus Sulphonylurea Receiving Either Canagliflozin or Sitagl... by Nuhoho, S, Worbes-Cerezo, M

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    PGI36 - Preferences for Route of Administration, Frequency and Location – A Time-Trade-Off Study in the United Kingdom General Population

    PGI36 - Preferences for Route of Administration, Frequency and Location – A Time-Trade-Off Study in the United Kingdom General Population by Jørgensen, T, Worbes-Cerezo, M, Lelli, F, Lee, XY, Bøgelund, M, Alulis, S

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Preferences for Route of Administration, Frequency and Location – A Time-Trade-Off Study in the United Kingdom General Population

    Preferences for Route of Administration, Frequency and Location – A Time-Trade-Off Study in the United Kingdom General Population by Jørgensen, T, Worbes-Cerezo, M, Lelli, F, Lee, XY, Bøgelund, M, Alulis, S

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    PGI33 - A Societal Utility Study to Elicit Values for Adverse Events and Surgical Complications in Moderate to Severe Crohn’s Disease in UK

    PGI33 - A Societal Utility Study to Elicit Values for Adverse Events and Surgical Complications in Moderate to Severe Crohn’s Disease in UK by Worbes-Cerezo, M, Nafees, B, Lloyd, AJ, Gallop, K, Ladha, I

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    A Societal Utility Study to Elicit Values for Adverse Events and Surgical Complications in Moderate to Severe Crohn’s Disease in UK

    A Societal Utility Study to Elicit Values for Adverse Events and Surgical Complications in Moderate to Severe Crohn’s Disease in UK by Worbes-Cerezo, M, Nafees, B, Lloyd, AJ, Gallop, K, Ladha, I

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    PDB139 - Health Related Quality of Life Outcomes (Hrqol) and Resource Use Associated With Type 2 Diabetes Patients Taking Steps To Lose Weight In 5 European Countries

    PDB139 - Health Related Quality of Life Outcomes (Hrqol) and Resource Use Associated With Type 2 Diabetes Patients Taking Steps To Lose Weight In 5 European Countries by Nuhoho, S., Vietri, J., Isherwood, G., Worbes-Cerezo, M.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    PGI31 - Key Drivers of Cost Effectiveness In Crohn’s Disease

    PGI31 - Key Drivers of Cost Effectiveness In Crohn’s Disease by Sly, IE, Worbes-Cerezo, M, Cranmer, H, Thompson, G, Almond, C

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Key Drivers of Cost Effectiveness In Crohn’s Disease

    Key Drivers of Cost Effectiveness In Crohn’s Disease by Sly, IE, Worbes-Cerezo, M, Cranmer, H, Thompson, G, Almond, C

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: